Journal of Clinical Oncology

HLA associations with immunotherapy related endocrine toxicity.

Journal of Clinical Oncology

Zoe Quandt, Christian Thorball, Pooja Middha, Douglas Buckner Johnson, Cosmin A Bejan, Lydia Yao, Yaomin Xu, Flavia Hodel, Athina Stravodimou, Esther Shearer-Kang, Geoffrey Liu, Melinda C Aldrich, Adam Jacob Schoenfeld, Elad Ziv, Elizabeth J Phillips, Jacques Fellay, Ewa A Bergmann, G Scott Chandler, Justin M Balko, Ashis Saha

Covalent-103: A phase 1, open-label, dose-escalation and expansion study of BMF-500, an oral covalent FLT3 inhibitor, in adults with acute leukemia (AL).

Journal of Clinical Oncology

Marcello Rotta, Yasmin Abaza, Hetty E Carraway, Bradley W. Christensen, Mitul Gandhi, Paul B. Koller, Ayman H. Qasrawi, Gary J. Schiller, Catherine Choy Smith, Uzma Ahmed, Alexandru Cacovean, Nicole Kowalczyk, Stephan W. Morris, Mona Vimal, Sauji Yachamaneni, Thomas Butler, Eunice S. Wang, Farhad Ravandi-Kashani

Association of germline polygenic risk for thyroid autoimmunity with overall survival in the I-SPY2 Trial.

Journal of Clinical Oncology

Kirkpatrick B Fergus, Pooja Middha, Zoe Quandt, Yiwey Shieh, Amrita B Basu, Rosalyn Sayaman, Paula R Pohlmann, Douglas Yee, Rebecca Arielle Shatsky, Claudine Isaacs, Michael J. Campbell, Gillian L. Hirst, Lamorna Brown Swigart, Laura van 't Veer, Elad Ziv, Laura Esserman

A phase 1 dose escalation study of a novel coupled CAR T cell therapy, GCC19CART, for patients with metastatic colorectal cancer.

Journal of Clinical Oncology

Benjamin L. Schlechter, Christopher Hanyoung Lieu, Marwan Fakih, Rishi Surana, Dongqi Chen, Lucy Lu, Eric Keith Rowinsky, Victor Lu, Lei Xiao, Kimmie Ng, Bridget P. Keenan

Therapeutic response and outcomes with less common breast cancer subtypes in the I-SPY trial 2011-2022.

Journal of Clinical Oncology

Alexandra Thomas, Denise M. Wolf, Ronald Balassanian, Yunn-Yi Chen, Julia Ye, Poonam Vohra, Evin H Gulbahce, Alexander D. Borowsky, Lamorna Brown Swigart, Gillian L. Hirst, Sara Venters, Rita Nanda, Rebecca Arielle Shatsky, Ralph D'Agostino, Rita A. Mukhtar, Sarah Hatcher, Christina Yau, Angela DeMichele, Laura van 't Veer, Laura Esserman

Impact of extent of disease at presentation on oncologic outcomes according to pathologic response to neoadjuvant systemic therapy among participants of the I-SPY2 clinical trial.

Journal of Clinical Oncology

Roberto Antonio Leon-Ferre, Katrina Dimitroff, Christina Yau, Karthik Giridhar, Rita A. Mukhtar, Gillian L. Hirst, Nola Hylton, W. Fraser Fraser Symmans, Matthew P. Goetz, Laura Esserman, Judy Caroline Boughey

Elucidating the immune active state of HR+HER2- MammaPrint High 2 early breast cancer.

Journal of Clinical Oncology

Erin Frances Cobain, Lajos Pusztai, Cathy Lynne Graham, Pat W. Whitworth, Peter D. Beitsch, Cynthia R. C. Osborne, Rakhshanda Layeequr Rahman, Nathalie MCDOWELL Johnson, Adam Brufsky, Reshma L. Mahtani, VK Gadi, Kent Hoskins, Hannah M. Linden, Rita A. Mukhtar, Laura Esserman, Josien Haan, Katie Quinn, Andrea Menicucci, M. William Audeh, Joyce O'Shaughnessy

Incidence and time to onset of immunotherapy-related adrenal insufficiency in the I-SPY2 trial.

Journal of Clinical Oncology

Rita Nanda, Ronald Cohen, Zoe Quandt, Amrita B Basu, Christina Yau, Amy Jo Chien, Lajos Pusztai, Hyo S. Han, Erica Michelle Stringer-Reasor, Claudine Isaacs, Dawn L. Hershman, Rebecca Arielle Shatsky, Jane Perlmutter, Douglas Yee, Angela DeMichele, Laura van 't Veer, Nola Hylton, Laura Esserman, Hope S. Rugo

ATHENA: A phase 1/2 study of AZD5851, a chimeric antigen receptor (CAR) T-cell therapy directed against GPC3 in adult patients with advanced/recurrent hepatocellular carcinoma (HCC).

Journal of Clinical Oncology

Ashley Hamilton, Robin Kate Kelley, Daneng Li, Ignacio Melero Bermejo, Ghassan K. Abou-Alfa, Olatunji B. Alese, Raed Moh'd Taiseer Al-Rajabi, Hani M. Babiker, Mitesh Borad, Farshid Dayyani, Martin Gutierrez, Jung Yong Hong, Lionel Aurelien Kankeu Fonkoua, Thomas Benjamin Karasic, Adel Kardosh, Bridget P. Keenan, Anne M. Noonan, Anwaar Saeed, Attilio Bondanza, John Stone

A first-in-human phase I study of ATG-031, anti-CD24 antibody, in patients with advanced solid tumors or B-cell non-Hodgkin lymphomas (PERFORM).

Journal of Clinical Oncology

Siqing Fu, Sarina A. Piha-Paul, Shivani Singh, Jing Peng, Bridget P. Keenan, Jay M. Mei, Kevin Lynch, Ling Li, Ming Song, Xiaojing (Amily) Zhang

Pages